Abstract
Genomic epidemiology study of Klebsiella pneumoniae causing bloodstream infections in China.
Highlights
A total of 239 Kpns were identified by screening 1219 Gram-negative bacteria causing BSI from 24 representative hospitals in different regions of China in 2018 (Table 1 and Figure 1; Table S1 and Figure S1)
Acquired antimicrobial resistance (AMR) gene analysis showed that all 239 strains acquired AMR genes conferring resistance to more than three drug classes (Table S6; Figures S4 and S5)
(82/239, 34.31%)-encoding genes, peg[344] (113/239, 47.28%), rmpA (113/239, 47.28%) and rmpA2 (98/238, 41%), which have been suggested to be the most predictive for hypervirulence,[7] were detected in >30% BSI-Kpns. They were more prevalent in ST23/ST65/K1/K2 (100% in ST23/ST65; 96.3% in K1/K2 except for rmpA2)
Summary
Genomic epidemiology study of Klebsiella pneumoniae causing bloodstream infections in China. Dear Editor, Klebsiella pneumoniae (K. pneumoniae, Kpn) bloodstream infection (BSI) has a considerable prevalence and high mortality worldwide.[1,2,3] The emergence of carbapenemresistant BSI-Kpns, especially those with hypervirulence, poses a challenge for BSI-Kpn control worldwide.[4,5,6] We conducted a large-scale multicenter epidemiological study and in-depth genomic analysis of BSI-Kpns in China, describing a complete molecular epidemiological picture (clinical features, sequence types (STs)/serotypes, antimicrobial resistance/hypervirulence, phenotype/genotype) of BSI-Kpns. A total of 239 Kpns were identified by screening 1219 Gram-negative bacteria causing BSI from 24 representative hospitals in different regions of China in 2018 (Table 1 and Figure 1; Table S1 and Figure S1). Twelve O-loci were detected, O1 and O2 were the most common, together accounting for 79.5% (190/239) of BSI-Kpns (Table 1). The most common carbapenemase was blaKPC-2, varying widely between different STs/serotypes (93.85% [61/65] ST11, 100% [14/14] K47, 86.79% [46/53] K64 strains and 0% of ST23/ST65/K1/K2 strains) (Table S8, Figure S4C).
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
